External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme

BACKGROUND AND AIMS: Trastuzumab provides clinical benefit for advanced and early breast cancer patients whose tumours over‐express or have gene amplification of the HER2 oncogene. The UK National External Quality Assessment Scheme (NEQAS) for immunohistochemical testing was established to assess an...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Bartlett, John M S, Ibrahim, Merdol, Jasani, Bharat, Morgan, John M, Ellis, Ian, Kay, Elaine, Magee, Hilary, Barnett, Sarah, Miller, Keith
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMJ Group 2007
विषय:
Original Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC1995794/
https://ncbi.nlm.nih.gov/pubmed/16963466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jcp.2006.040840
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन